Evidence map›Paper›PMID 39676870›Full record

ArticleFrontiers in immunology2024

ID1 and ID3 functions in the modulation of the tumour immune microenvironment in adult patients with B-cell acute lymphoblastic leukaemia.

Nathaly Poveda-Garavito, Carlos A Orozco Castaño, Yulieth Torres-Llanos, Nataly Cruz-Rodriguez, Rafael Parra-Medina, Sandra Quijano, Jovanny Zabaleta, Alba Lucia Combita

Abstract read
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Nathaly Poveda-GaravitoGrupo de Investigación en Biología del Cáncer - Instituto Nacional de Cancerología, Bogotá, Colombia.
Carlos A Orozco CastañoGrupo de Investigación en Biología del Cáncer - Instituto Nacional de Cancerología, Bogotá, Colombia.
Yulieth Torres-LlanosGrupo de Investigación en Biología del Cáncer - Instituto Nacional de Cancerología, Bogotá, Colombia.
Nataly Cruz-RodriguezStem Cell Program, Versiti Blood Research Institute, Milwaukee, WI, United States.
Rafael Parra-MedinaDepartamento de Patología, Instituto Nacional de Cancerología, Bogotá, Colombia.
Sandra QuijanoGrupo de Inmunobiología y Biología Celular, Departamento de Microbiología, Pontificia Universidad Javeriana, Bogotá, Colombia.
Jovanny ZabaletaDepartment of Interdisciplinary Oncology, Louisiana State University Health Sciences Center, New Orleans, LA,  United States.
Alba Lucia CombitaGrupo de Investigación en Biología del Cáncer - Instituto Nacional de Cancerología, Bogotá, Colombia.

Funding

Translational Genomics Core (TGC)P20GM121288 · NIGMS · LSU HEALTH SCIENCES CENTER · PI Arunava Roy · 2017 to 2026
$22.4M
NIGMS NIH HHS P20 GM121288
6 · The paper itself

Abstract

Introduction: B-cell acute lymphoblastic leukemia (B-ALL) in adults often presents a poor prognosis. ID1 and ID3 genes have been identified as predictors of poor response in Colombian adult B-ALL patients, contributing to cancer development. In various cancer models, these genes have been associated with immune regulatory populations within the tumor immune microenvironment (TIME). B-ALL progression alters immune cell composition and the bone marrow (BM) microenvironment, impacting disease progression and therapy response. This study investigates the relationship between ID1 and ID3 expression, TIME dynamics, and immune evasion mechanisms in adult B-ALL patients. Methods: This exploratory study analysed BM samples from 10 B-ALL adult patients diagnosed at the National Cancer Institute of Colombia. First, RT-qPCR was used to assess ID1 and ID3 expression in BM tumour cells. Flow cytometry characterised immune populations in the TIME. RNA-seq evaluated immune genes associatedwith B-ALL immune response, while xCell and CytoSig analysed TIME cell profiles and cytokines. Pathway analysis, gene ontology, and differential gene expression (DEGs) were examined, with functional enrichment analysis performed using KEGG ontology. Results: Patients were divided into two groups based on ID1 and ID3 expression, namely basal and overexpression. A total of 94 differentially expressed genes were identified between these groups, with top overexpressed genes associated with neutrophil pathways. Gene set enrichment analysis revealed increased expression of genes associated with neutrophil degranulation, immune response-related neutrophil activation, and neutrophil-mediated immunity. These findings correlated with xCell data. Overexpression group showed significant differences in neutrophils, monocytes and CD4+ naive T cells compared to basal group patients. Microenvironment and immune scores were also significantly different, consistent with the flow cytometry results. Elevated cytokine levels associated with neutrophil activation supported these findings. Validation was performed using the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) TCGA B-ALL cohorts. Discussion: These findings highlight significant differences in ID1 and ID3 expression levels and their impact on TIME populations, particularly neutrophil-related pathways. The results suggest a potential role for ID1 and ID3 in immune evasion in adult B-ALL, mediated through neutrophil activation and immune regulation.

Indexed as

Inhibitor of Differentiation Protein 1Inhibitor of Differentiation ProteinsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaTumor MicroenvironmentAdultBone MarrowFemaleGene Expression Regulation, LeukemicHumansMaleMiddle AgedNeoplasm ProteinsYoung AdultID1 protein, humanID3 protein, humanInhibitor of Differentiation Protein 1Inhibitor of Differentiation ProteinsNeoplasm ProteinsB-cell acute lymphoblastic leukaemia (B-ALL)bone marrowimmune evasionimmune systemimmunosurveillancemicroenvironment

Identifiers

PMID39676870
PMCPMC11638060

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.